[go: up one dir, main page]

UY30501A1 - Neurotrofinas modificadas post-trasduccionalmente - Google Patents

Neurotrofinas modificadas post-trasduccionalmente

Info

Publication number
UY30501A1
UY30501A1 UY30501A UY30501A UY30501A1 UY 30501 A1 UY30501 A1 UY 30501A1 UY 30501 A UY30501 A UY 30501A UY 30501 A UY30501 A UY 30501A UY 30501 A1 UY30501 A1 UY 30501A1
Authority
UY
Uruguay
Prior art keywords
post
neurotrophins
modified
pro
compounds
Prior art date
Application number
UY30501A
Other languages
English (en)
Inventor
Pedro M Alzari
Patricia Cassina
Mariana Pehar
Luis Barbeito
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY30501A1 publication Critical patent/UY30501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

La presente invención describe que las neurotrofinas sufren modificaciones post-transduccionales y estas modificaciones post-transduccionales median la actividad pro-apoptótica y/o pro-neuritas de las neurotrofinas. Estas modificaciones post-transduccionales incluyen notablemente la nitración y la formación de dímeros de diferente conformación, así como también de oligómeros anormales, tales como tetrámeros y octámeros. La invención se refiere además a los compuestos que compiten con dichas neurotrofinas modificadas, así como también compuestos que se unen a dichas neurotrofinas modificadas. La invención provee así agentes útiles para el tratamiento de las condiciones o enfermedades que involucran dolor crónico y/o pérdidas neuronales.
UY30501A 2006-07-24 2007-07-24 Neurotrofinas modificadas post-trasduccionalmente UY30501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291195A EP1882697B1 (en) 2006-07-24 2006-07-24 Antibodies, antibody fragments and scFv binding to post-translationally modified neurotrophins

Publications (1)

Publication Number Publication Date
UY30501A1 true UY30501A1 (es) 2009-04-30

Family

ID=37075006

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30501A UY30501A1 (es) 2006-07-24 2007-07-24 Neurotrofinas modificadas post-trasduccionalmente

Country Status (10)

Country Link
US (2) US20100055109A1 (es)
EP (2) EP1882697B1 (es)
JP (1) JP5528803B2 (es)
AR (1) AR062038A1 (es)
AT (1) ATE465179T1 (es)
BR (1) BRPI0714545A2 (es)
CA (1) CA2657563A1 (es)
DE (1) DE602006013809D1 (es)
UY (1) UY30501A1 (es)
WO (1) WO2008012049A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE465179T1 (de) * 2006-07-24 2010-05-15 Pasteur Institut Antikörper, antikörperfragmente und scfv die an posttranslational modifizierte neurotrophine binden
WO2012033916A1 (en) * 2010-09-08 2012-03-15 Southern Illinois University Edwardsville Method for treating chronic pain
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US8728473B2 (en) 2010-12-01 2014-05-20 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
WO2018148507A1 (en) * 2017-02-10 2018-08-16 Vivibaba, Inc Compositions and methods for recombinant nerve growth factor
AU2019243155A1 (en) * 2018-03-27 2020-10-15 Factor Bioscience Inc. Nucleic acid-based therapeutics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
US6068040A (en) 1998-07-24 2000-05-30 Alpine Overhead Doors, Inc. Slat edge retainer for overhead rolling doors
EP1500399A1 (en) * 2003-07-24 2005-01-26 Institut Pasteur Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases
ATE465179T1 (de) * 2006-07-24 2010-05-15 Pasteur Institut Antikörper, antikörperfragmente und scfv die an posttranslational modifizierte neurotrophine binden

Also Published As

Publication number Publication date
HK1116806A1 (en) 2009-01-02
EP1882697B1 (en) 2010-04-21
US20140178384A1 (en) 2014-06-26
WO2008012049A1 (en) 2008-01-31
CA2657563A1 (en) 2008-01-31
DE602006013809D1 (de) 2010-06-02
US9328163B2 (en) 2016-05-03
US20100055109A1 (en) 2010-03-04
EP1882697A1 (en) 2008-01-30
EP2046823B1 (en) 2012-11-21
JP5528803B2 (ja) 2014-06-25
ATE465179T1 (de) 2010-05-15
BRPI0714545A2 (pt) 2013-05-14
AR062038A1 (es) 2008-08-10
JP2010501475A (ja) 2010-01-21
EP2046823A1 (en) 2009-04-15

Similar Documents

Publication Publication Date Title
UY30501A1 (es) Neurotrofinas modificadas post-trasduccionalmente
ECSP12011622A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
CU20120099A7 (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
EA200870556A1 (ru) Комбинированная терапия в лечении эпилепсии и родственных расстройств
GT200600297A (es) Nuevos anticuerpos anti-madcam
PA8680701A1 (es) Derivados de oxindol
GT200900123A (es) Compuestos y metodos para inhibir la interacción de las proteinas bcl con molécula de enlace
CR10310A (es) Compuestos nuevos
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
GT201300179A (es) Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
BR112012028451A2 (pt) composição tópica de iodopovidona
UY30282A1 (es) Compuestos quimicos
CR9667A (es) Derivados de benzamida y usos relacionados con los mismos
AR085219A1 (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc
UY31539A1 (es) Agentes antelminticos y su uso
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
CO2017004994A2 (es) Análogos de urea unidos sustituidos como moduladores de sirtuina
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
BRPI0512322A (pt) desinfetante para combater fungos fitopatogênicos
GT200500360A (es) Compuestos organicos
ECSP088607A (es) Compuestos y métodos para inhibir la interacción de las proteínas bcl con las parejas de unión
UY29161A1 (es) Nuevos heterociclos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170724